Transcatheter Mitral and Tricuspid Therapies — Net Sales
Edwards Lifesciences Transcatheter Mitral and Tricuspid Therapies — Net Sales increased by 12.5% to $175.10M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 52.0%, from $115.20M to $175.10M. Over 4 years (FY 2021 to FY 2025), Transcatheter Mitral and Tricuspid Therapies — Net Sales shows an upward trend with a 59.1% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase indicates strong clinical adoption and successful commercialization of new structural heart therapies, while a decrease may signal competitive pressure or slower-than-expected market expansion for these specialized procedures.
Detailed definition
This metric represents the total revenue generated from the sale of medical devices designed for minimally invasive trea...
Peer comparison
Peers in the medical device sector often report similar revenue streams under 'Structural Heart' or 'Cardiovascular' segments, specifically focusing on transcatheter valve replacement and repair technologies.
ew_segment_transcatheter_mitral_and_tricuspid_therapies_net_salesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $22.10M | $22.30M | $25.30M | $27.00M | $27.90M | $29.70M | $31.50M | $41.60M | $47.60M | $52.40M | $56.00M | $72.90M | $83.00M | $91.10M | $105.10M | $115.20M | $134.50M | $145.20M | $155.70M | $175.10M |
| QoQ Change | — | +0.9% | +13.5% | +6.7% | +3.3% | +6.5% | +6.1% | +32.1% | +14.4% | +10.1% | +6.9% | +30.2% | +13.9% | +9.8% | +15.4% | +9.6% | +16.8% | +8.0% | +7.2% | +12.5% |
| YoY Change | — | — | — | — | +26.2% | +33.2% | +24.5% | +54.1% | +70.6% | +76.4% | +77.8% | +75.2% | +74.4% | +73.9% | +87.7% | +58.0% | +62.0% | +59.4% | +48.1% | +52.0% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Edwards Lifesciences's transcatheter mitral and tricuspid therapies — net sales?
- Edwards Lifesciences (EW) reported transcatheter mitral and tricuspid therapies — net sales of $175.10M in Q1 2026.
- How has Edwards Lifesciences's transcatheter mitral and tricuspid therapies — net sales changed year-over-year?
- Edwards Lifesciences's transcatheter mitral and tricuspid therapies — net sales increased by 52.0% year-over-year, from $115.20M to $175.10M.
- What is the long-term trend for Edwards Lifesciences's transcatheter mitral and tricuspid therapies — net sales?
- Over 4 years (2021 to 2025), Edwards Lifesciences's transcatheter mitral and tricuspid therapies — net sales has grown at a 59.1% compound annual growth rate (CAGR), from $86.00M to $550.60M.
- What does transcatheter mitral and tricuspid therapies — net sales mean?
- Total revenue earned from selling minimally invasive heart valve repair and replacement devices for the mitral and tricuspid valves.